Literature DB >> 11050528

Extracellular ATP couples to cAMP generation and granulocytic differentiation in human NB4 promyelocytic leukaemia cells.

L van der Weyden1, V Rakyan, B M Luttrell, M B Morris, A D Conigrave.   

Abstract

Priming of NB4 promyelocytic cells with all-trans retinoic acid, followed by extracellular ATP in the presence of a phosphodiesterase inhibitor, elevated cAMP and activated protein kinase A. The order of potency for cAMP production was ATP (EC50 = 95 +/- 13 micromol/L) > ADP > AMP = adenosine. The order of potency of ATP analogues was 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (EC50 = 54 +/- 15 micromol/L) = adenosine 5'-O-(3-thio) triphosphate (EC50 = 66 +/- 4 micromol/L) > ATP > beta,gamma-methylene ATP (EC50 = 200 +/- 55 micromol/L). Adenosine 5'-O-thiomonophosphate and adenosine 5'-O-(2-thio) diphosphate inhibited ATP-induced cAMP production. Differentiation also occurred as measured by increased expression of CD11b and N-formyl peptide receptor and changes in cell morphology. UTP did not elevate cAMP or induce differentiation, indicating that P2Y2, P2Y4, and P2Y6 receptors were not involved. The P2Y11 receptor, a cAMP-linked receptor on promyelocytic HL-60 cells, was detected in NB4 cells by reverse transcription-polymerase chain reaction and northern blotting. This receptor has the same order of potency with respect to cAMP production as that observed in HL-60 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050528     DOI: 10.1111/j.1440-1711.2000.t01-4-.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  10 in total

1.  ADP-sensitive purinoceptors induce steroidogenesis via adenylyl cyclase activation in bovine adrenocortical fasciculata cells.

Authors:  Haruhisa Nishi; Fusao Kato; Eiji Masaki; Masahiro Kawamura
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 2.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 3.  Expression and function of P2 receptors in hematopoietic stem and progenitor cells.

Authors:  Wenli Feng; Lina Wang; Guoguang Zheng
Journal:  Stem Cell Investig       Date:  2015-07-30

Review 4.  A critical look at the function of the P2Y11 receptor.

Authors:  Karin Dreisig; Birgitte Rahbek Kornum
Journal:  Purinergic Signal       Date:  2016-05-31       Impact factor: 3.765

5.  Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.

Authors:  Yael Nadel; Joanna Lecka; Yocheved Gilad; Gal Ben-David; Daniel Förster; Georg Reiser; Sarah Kenigsberg; Jean Camden; Gary A Weisman; Hanoch Senderowitz; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2014-05-30       Impact factor: 7.446

Review 6.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

7.  Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models.

Authors:  Xiaoxiao He; Jiangbo Wan; Xiaona Yang; Xiuze Zhang; Dan Huang; Xie Li; Yejun Zou; Chiqi Chen; Zhuo Yu; Li Xie; Yaping Zhang; Ligen Liu; Shangang Li; Yuzheng Zhao; Hongfang Shao; Ye Yu; Junke Zheng
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

8.  Pharmacological characterisation of the P2Y11 receptor in stably transfected haematological cell lines.

Authors:  L van der Weyden; D J Adams; B M Luttrell; A D Conigrave; M B Morris
Journal:  Mol Cell Biochem       Date:  2000-10       Impact factor: 3.396

9.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

10.  Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor.

Authors:  Kathryn R Vaughan; Leanne Stokes; Lynne R Prince; Helen M Marriott; Sabine Meis; Matthias U Kassack; Colin D Bingle; Ian Sabroe; Annmarie Surprenant; Moira K B Whyte
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.